Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
allogeneic cell therapy
Biotech
Sana shares 14-month data for ‘functional cure’ diabetes program
Sana is evaluating a donor-derived primary islet cell therapy designed to serve as a Type 1 diabetes treatment that doesn’t require immunosuppression.
Gabrielle Masson
Mar 13, 2026 10:55am
Allogeneic CAR-T biotechs fight to escape 'nuclear winter'
Feb 11, 2026 11:00am
ImmunityBio touts 15-month complete response in CAR-NK trial
Jan 16, 2026 9:19am
Novo calls off $598M Heartseed collab, citing 'strategic reviews'
Sep 30, 2025 1:55pm
Gilead's Kite erodes $2.3B Shoreline cell therapy deal
Sep 3, 2025 3:18pm
Wugen woos VCs, landing $115M to bring CAR-T therapy to market
Aug 27, 2025 8:10am
